sanofi returns TroVax rights

sanofi-aventis Group (Euronext:SAN; NYSE:SNY) returned to Oxford BioMedica plc (LSE:OXB) rights to TroVax following a

Read the full 153 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE